The Hyderabad based Bharat Biotech International Private Limited manufactured COVAXIN has been found effective against the new Delta Plus variant of the Wuhan virus.
The latest development regarding the Novel Coronavirus (COVID-19) vaccine was reported by the Indian Council of Medical Research (ICMR.) On the 2nd of August, the ICMR confirmed the efficiency of Bharat Biotech’s COVAXIN for the new variant.
The ICMR study report regarding the same read, “Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of COVID-19 naive individuals full doses of BBV152 vaccine, COVID-19 recovered cases with full dose vaccines and breakthrough cases post immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.” The study further read, “The research findings also suggested that a minor reduction was observed in the neutralizing antibody titer in covid-19 recovered cases, those who were fully vaccinated with COVAXIN, and post immunized infected cases, compared to COVID-19 naive vaccinated individuals. However, with the observed high titers in the sera (blood sample) of individuals belonging to all the aforementioned groups, they would still neutralize the Delta, Delta AY.1 and B.1.617.3 variants effectively.”
It is to be noted, the dangerous mutation of the deadly Wuhan virus is a matter of concern and has spread to nearly 132 countries including India. The World Health Organisation (WHO) also alerted countries to be cautious of the new variant of the COVID-19 infection.
The SARS-CoV-2 Variant B.1.617.2 (Delta) variant has high transmissibility, which also led to the second wave in India and is expected to bring the third wave of COVID-19. However, the Indian Government and governments of different states and union territories, are preparing to tackle the possible third wave of the Novel Coronavirus, along with the new variant. States like Kerala, West Bengal, Uttar Pradesh and Andhra Pradesh have imposed partial lockdowns, night curfews and restrictions to contain the spread of the virus.
In addition, with the report of COVAXIN being 65.20 % effective on the new variant, it is expected the supply of the India made COVID-19 would increase.
Mango News Link:
Telegram: https://t.me/mangonewsofficial
Google Play Store: https://bit.ly/2R4cbgN
Apple / iOS Store: https://apple.co/2xEYFJ
